Omada Health Reports Strong Q2 2026 Growth Amid CEO Transition
Event summary
- Omada Health reported Q2 2026 revenue of $88 million, up 43% YoY.
- Total members increased by 45% YoY, with gross margin reaching a record 73%.
- Sean Duffy will transition to Executive Chair on January 1, 2027, with Wei-Li Shao becoming CEO.
- The company expanded its partnership with HCSC, adding 1.5 million covered lives.
- Adjusted EBITDA for Q2 2026 was $11 million, compared to a loss of $0.2 million in Q2 2025.
The big picture
Omada Health's strong Q2 2026 results reflect growing demand for virtual care solutions in chronic disease management. The CEO transition signals a strategic shift, with Wei-Li Shao bringing deep experience from Eli Lilly and Company to drive further scalability. The company's expanded partnership with HCSC underscores its position as a key player in the digital health sector.
What we're watching
- Leadership Transition Impact
- How Wei-Li Shao's transition to CEO will affect Omada Health's strategic direction and execution.
- Market Expansion
- The pace at which Omada can sustain its 43% revenue growth amid increasing competition in virtual care.
- Operational Efficiency
- Whether the company can maintain its record gross margin of 73% while scaling operations.
Related topics